LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use Share Post Post navigation Previous PostERAS Investors Have Opportunity to Lead Erasca, Inc. Securities Fraud LawsuitNext Post Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma